Skip to main content
EU expands label of Amgen's Repatha

Amgen's Repatha, or evolocumab, was approved by the European Commission to reduce low-density lipoprotein levels in adult patients with atherosclerotic cardiovascular disease to reduce cardiovascular risk. A FOURIER cardiovascular outcomes study showed that treatment with Repatha plus statins lessened the risk of heart attack by 27%, stroke by 21% and coronary revascularization procedures by 22% compared with statin therapy plus placebo over a 26-month treatment period.

Full Story: